Orion Pharma and Orion Infusion, two listed concerns Orion Group, posted contrasting financial results for the fiscal year that ended on June 30, 2024.

Orion Pharma's profit declined 50 percent year-on-year to Tk 31.82 crore.

Its consolidated earnings per share (EPS) fell to Tk 1.36 from Tk 2.74 in the previous year, according to a disclosure on the website of the Dhaka Stock Exchange.

Its net operating cash flow per share (NOCFPS) also weakened, with a consolidated NOCFPS of Tk 6.78, down from Tk 10.65 in FY23.

However, Orion Pharma's board recommended a 10 percent cash dividend for its shareholders.

In contrast, Orion Infusion posted a 1 percent increase in profit as it made Tk 4.23 crore in the same period. As a result, Infusion's EPS went up to Tk 2.08 from Tk 2.06.

Its cash flow stood at Tk 2.82, slightly lower than the previous year's Tk 2.98.

The board of Orion Infusion recommended a 12 percent cash dividend.